Signal
Intellia files for FDA approval after successful phase 3 trial of in vivo CRISPR therapy
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-27 12:48 UTCUpdated 2026-04-27 13:33 UTC
rss
clinical_trialsfdadrug_developmentgene_editingr_and_d
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 top sources shown
Overview
Intellia Therapeutics announced that its in vivo gene editing therapy, lonvoguran ziclumeran, met the primary endpoint in a phase 3 trial targeting hereditary angioedema.
Entities
Intellia Therapeuticslonvoguran ziclumeran
Score total
1.28
Momentum 24h
3
Posts
3
Origins
3
Source types
1
Duplicate ratio
0%
Why now
- Phase 3 data recently announced confirming primary endpoint achievement.
- Intellia has just initiated rolling FDA submission, accelerating regulatory review.
- Investor and industry focus intensifies on gene editing therapies following this breakthrough.
Why it matters
- Represents a milestone as the first potential in vivo gene editing medicine to reach FDA submission.
- Validates CRISPR technology in a late-stage clinical trial for a rare genetic disorder.
- Could pave the way for new gene editing therapies targeting other diseases.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Intellia's in vivo CRISPR therapy lonvoguran ziclumeran met the primary endpoint in a phase 3 trial for hereditary angioedema.
- Following the phase 3 success, Intellia has initiated a rolling submission for FDA approval.
How sources frame it
- Ben Fidler: neutral
- Phil.Taylor: neutral
- Unknown: neutral
This narrative highlights a key advancement in gene editing therapy with Intellia's phase 3 success and FDA filing, marking a potential first in vivo CRISPR medicine.
All evidence
All evidence
Intellia files CRISPR drug after historic phase 3 readout
pharmaphorum · pharmaphorum.com · 2026-04-27 13:33 UTC
A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran has hit its primary endpoint, leading the biotech to start a rolling submission for ...
Fierce Biotech · fiercebiotech.com · 2026-04-27 13:28 UTC
Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
BioPharma Dive · biopharmadive.com · 2026-04-27 12:48 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- pharmaphorum (1)
- Fierce Biotech (1)
- BioPharma Dive (1)
Top origin domains (this list)
- pharmaphorum.com (1)
- fiercebiotech.com (1)
- biopharmadive.com (1)